PDF herunterladen
Thromb Haemost 2016; 116(02): 397-400
DOI: 10.1160/TH16-02-0101
Letters to the Editor
Schattauer GmbH

Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases

Joseph J. Shatzel
Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, USA
,
Meg Crapster-Pregont
Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, USA
,
Thomas G. Deloughery
Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 07. Februar 2016

Accepted after major revision: 31. März 2016

Publikationsdatum:
11. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Supplementary Material to this article is available at www.thrombosis-online.com.

 

  • References

  • 1 Horsewood P, Warkentin TE, Hayward CPM. et al. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996; 95: 161-167.
    CrossrefPubMedGoogle Scholar
  • 2 Warkentin TE, Kelton JG.. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507.
    CrossrefPubMedGoogle Scholar
  • 3 Nand S, Wong W, Yuen B. et al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12-16.
    CrossrefPubMedGoogle Scholar
  • 4 Lewis BE, Wallis DE, Berkowitz SD. et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
    CrossrefPubMedGoogle Scholar
  • 5 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl) e495S-530S.
    CrossrefPubMedGoogle Scholar
  • 6 Chai-Adisaksopha C, Crowther M, Isayama T. et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450-2458.
    CrossrefPubMedGoogle Scholar
  • 7 Chai-Adisaksopha C, Hillis C, Isayama T. et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13: 2012-2020.
    CrossrefPubMedGoogle Scholar
  • 8 Linkins LA, Warkentin TE, Pai M. et al. Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis 2014; 38: 485-492.
    CrossrefPubMedGoogle Scholar
  • 9 Walenga JM, Prechel M, Jeske WP. et al. Rivaroxaban--an oral, direct Factor Xa inhibitor—has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol 2008; 143: 92-99.
    CrossrefPubMedGoogle Scholar
  • 10 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 340S-380S.
    CrossrefPubMedGoogle Scholar
  • 11 Warkentin TE.. Ischemic Limb Gangrene with Pulses. N Engl J Med 2015; 373: 642-655.
    CrossrefPubMedGoogle Scholar
  • 12 Kunk P, Macik BG, Brown J.. Abstract number 3547 Non-Warfarin Oral Anticoagulants in Heparin-Induced Thrombocytopenia. American Society of Hematology 57th annual meeting. Orlando FL: 2015. Dec.
    Google Scholar
  • 13 Linkins LA, Warkentin TE, Pai M. et al. Abstract number 3468 Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. American Society of Hematology 57th annual meeting. Orlando FL: 2015. Dec.
    Google Scholar
  • 14 Ng HJ, Than H, Teo EC.. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. Thromb Res 2015; 135: 205-207.
    CrossrefPubMedGoogle Scholar
  • 15 Mirdamadi A.. Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. ARYA Atheroscler 2013; 9: 112-114.
    PubMedGoogle Scholar
  • 16 Hantson P, Lambert C, Hermans C.. Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 2015; 26: 205-206.
    CrossrefPubMedGoogle Scholar
  • 17 Sartori M, Favaretto E, Cini M. et al. Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia. J Thromb Thrombolysis 2015; 40: 392-394.
    CrossrefPubMedGoogle Scholar
  • 18 Larsen PB, Jørgensen M, Friis-Hansen L. et al. Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer. Clin Case Rep 2015; 3: 987-989.
    CrossrefPubMedGoogle Scholar
  • 19 Sharifi M, Bay C, Vajo Z. et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. Thromb Res 2015; 135: 607-609.
    CrossrefPubMedGoogle Scholar
  • 20 Abouchakra L, Khabbaz Z, Abouassi S. et al. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report. J Thorac Cardiovasc Surg 2015; 150: e19-20.
    CrossrefPubMedGoogle Scholar
  • 21 Kopolovic I, Warkentin TE.. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. CMAJ 2014; 186: 929-933.
    CrossrefPubMedGoogle Scholar